Telehealth companies hired by employers to manage obesity drug costs are facing criticism for potentially limiting patient access to medications like Zepbound and Wegovy. Patients report being forced to try generic drugs first or facing hurdles that lead to out-of-pocket expenses, while doctors express concern over these companies offering medical advice outside their scope.
Telehealth companies hired by employers to manage obesity drug costs are increasingly criticized for prioritizing cost-cutting over patient care. Patients report being forced to try less effective generic drugs or face denial of access to crucial medications like Zepbound and Wegovy, leading to frustration and weight regain.
Online telehealth pharmacies are booming, selling GLP-1s and weight-loss drugs. However, many consumers report being charged for unsolicited medications, facing impossible cancellation policies, and experiencing unresponsive customer service, leading to significant financial losses and frustration.
Novo Nordisk has launched its weight loss pill Wegovy in the United Arab Emirates, marking its first expansion outside the U.S. market. The drug's approval by the Emirates Drug Establishment follows recent competition from Eli Lilly in the growing obesity drug sector.
The Supreme Court upheld access to the abortion pill mifepristone, Trump returned from a state visit to China with announced but unconfirmed purchases, and the UK faces political turmoil with challenges to Prime Minister Keir Starmer's leadership.
After an appeals court tried to end telemedicine access to mifepristone, one of the two pills used in a medication abortion, the Supreme Court stepped in. Here's what's happened and what's to come.
Despite voluntary assisted dying being legal in Victoria, many regional patients are not getting the same end-of-life care.
